Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus target price of $3.50 for the company and are expecting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 183 out of 265 based on the ratings given to related companies.
Several analysts recently issued reports on the company. Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Thursday. Maxim Group set a $4.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, March 28th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of AEterna Zentaris in a research note on Thursday, March 29th. Finally, ValuEngine raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
NASDAQ AEZS opened at $1.35 on Thursday. AEterna Zentaris has a 1 year low of $0.78 and a 1 year high of $3.75.
TRADEMARK VIOLATION NOTICE: “Zacks: AEterna Zentaris Inc. (AEZS) Given $3.50 Consensus Target Price by Analysts” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3340927/zacks-aeterna-zentaris-inc-aezs-given-3-50-consensus-target-price-by-analysts.html.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.